Loreley Calvet

TL;DR: An extensive in vivo analysis of patient-derived xenograft models for CRC shows the loss of human stroma cells after engraftment, observed a metastatic phenotype in some models, and compared the molecular profile with the drug sensitivity of each tumor model.

TL;DR: Cabazitaxel is as active as docetaxel in docentaxel-sensitive tumor models but is more potent than docetAXel in tumor models with innate or acquired resistance to taxanes and other chemotherapies.

TL;DR: It is found that BRAF-like CCs display far greater sensitivity to the microtubule poison vinorelbine both in vitro and in vivo, suggesting that vinORElbine is a potential tailored treatment for BRAF/V600E CCs.

TL;DR: A combination of semisynthesis of microbially derived bengamides and total synthesis resulted in an optimized derivative that combined high cellular potency in the nanomolar range with high metabolic stability, which translated to an improved half-life in mice and antitumor efficacy in a melanoma mouse model.

TL;DR: It is demonstrated that SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile, supporting its clinical development in patients with MET-amplified and MET pathway–addicted tumors.